Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834167 | 0.91 | NAMPT (0.55) | NAMPTALDH1A1SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL6833501 | 0.90 | NAMPT (0.45) | NAMPTALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL6831069 | 0.86 | NAMPT (0.53) | NAMPTALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL6834410 | 0.82 | NPC1 (0.36) | ALDH1A1SMN1; SMN2KDM4EHTT | |
| SCHEMBL6309958 | 0.80 | ALDH1A1 (0.42) | NAMPTALDH1A1TSHRKDM4EMEN1 | |
| SCHEMBL6303008 | 0.80 | ALDH1A1 (0.44) | NAMPTALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL6835981 | 0.79 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2HSD17B10TSHRKDM4E | |
| SCHEMBL7222958 | 0.77 | NPSR1 (0.34) | NAMPTALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL7386449 | 0.74 | ALDH1A1 (0.48) | NAMPTALDH1A1HSD17B10TSHRKDM4E | |
| SCHEMBL7218258 | 0.73 | GCK (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | NAMPT 2347/4885ALDH1A1 1197/4885SMN1; SMN2 3794/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | NAMPT 2347/4885ALDH1A1 1197/4885SMN1; SMN2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.